Overview
Symbiotic Capital Management Co. LLC (“Symbiotic Capital,” the “Adviser,” “our,” or “we”)
is a Delaware limited liability company located in Los Angeles, California, and founded in
September 2022 by Symbiotic Capital, LLC.
Symbiotic Capital is a first-of-its-kind life science credit platform and aspires to be the preferred
credit partner for innovative life science companies. The Adviser is backed by Bellco Capital LLC’s
(“Bellco Capital”) preeminent life science ecosystem, which, over the past three decades, has
incubated and built leading life science companies (such as Kite Pharma), invested in
transformational science, and developed life science real estate across the globe. Symbiotic
Capital’s participation in this ecosystem actively empowers our investment sourcing and portfolio
value creation. In addition, Symbiotic Capital has access to numerous companies, academia,
investors, and pharma partners via the Bellco Capital life science ecosystem and will seek to
leverage these relationships across all aspects of the credit business, from deal sourcing to adding
value to the underlying borrowers.
Symbiotic Capital provides advisory services to the Symbiotic Life Sciences Credit Fund and the
Symbiotic Capital Life Science Credit Parallel Fund GP, L.P. (the “Funds” or the “Clients”). The
Funds offer investors the opportunity to own a curated portfolio of secured credit investments in the
development stage and commercial stage life science companies. Symbiotic Capital focuses on
looking for opportunities to enhance borrower value through the life of the loan and, as necessary,
to leverage its life science heritage and ecosystem to manage downside scenarios.
As of December 2023, Symbiotic Capital has $252,499,111 in discretionary assets under
management.
Persons reviewing this Form ADV Part 2A should not construe this as an offering of the Funds
described herein, which will only be made pursuant to the delivery of a private placement
memorandum, subscription agreement, and/or similar documentation to prospective investors.
Symbiotic Capital does not participate in wrap fee programs or advise client assets on a non-
discretionary basis.